These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 17261633)

  • 1. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation.
    Ford ML; Koehn BH; Wagener ME; Jiang W; Gangappa S; Pearson TC; Larsen CP
    J Exp Med; 2007 Feb; 204(2):299-309. PubMed ID: 17261633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection.
    Ford ML; Wagener ME; Hanna SS; Pearson TC; Kirk AD; Larsen CP
    J Immunol; 2008 Jun; 180(11):7203-11. PubMed ID: 18490719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection.
    Vu MD; Amanullah F; Li Y; Demirci G; Sayegh MH; Li XC
    J Immunol; 2004 Jul; 173(1):214-21. PubMed ID: 15210777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-frequency alloreactive T cells augment effector function of low-frequency CD8+ T-cell responses under CD28/CD154 blockade.
    Floyd TL; Orr SB; Coley SM; Hanna SS; Wagener ME; Kirk AD; Larsen CP; Ford ML
    Transplantation; 2010 May; 89(10):1208-17. PubMed ID: 20407401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of OX40 in CD28 and CD154-independent rejection.
    Demirci G; Amanullah F; Kewalaramani R; Yagita H; Strom TB; Sayegh MH; Li XC
    J Immunol; 2004 Feb; 172(3):1691-8. PubMed ID: 14734751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY; Lee EN; Lee J; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Joh JW; Kim SJ
    Exp Mol Med; 2006 Jun; 38(3):284-94. PubMed ID: 16819287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of allorecognition and skin graft rejection in CD28 and CD40 ligand double-deficient mice.
    Habiro K; Kotani M; Omoto K; Kobayashi S; Tanabe K; Shimmura H; Suzuki K; Hayashi T; Toma H; Abe R
    Transplantation; 2003 Sep; 76(5):854-8. PubMed ID: 14501867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.
    Zhai Y; Meng L; Gao F; Busuttil RW; Kupiec-Weglinski JW
    J Immunol; 2002 Oct; 169(8):4667-73. PubMed ID: 12370407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New insights in CD28-independent allograft rejection.
    Habicht A; Najafian N; Yagita H; Sayegh MH; Clarkson MR
    Am J Transplant; 2007 Aug; 7(8):1917-26. PubMed ID: 17617854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different costimulation signals used by CD4(+) and CD8(+) cells that independently initiate rejection of allogenic hepatocytes in mice.
    Gao D; Li J; Orosz CG; Bumgardner GL
    Hepatology; 2000 Nov; 32(5):1018-28. PubMed ID: 11050052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance.
    Jarvinen LZ; Blazar BR; Adeyi OA; Strom TB; Noelle RJ
    Transplantation; 2003 Nov; 76(9):1375-9. PubMed ID: 14627918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
    Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
    Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: CD4+CD25+ alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: implications for anti-CD154 immunotherapy.
    van Maurik Av; Herber M; Wood KJ; Jones ND
    J Immunol; 2002 Nov; 169(10):5401-4. PubMed ID: 12421913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On CD28/CD40 ligand costimulation, common gamma-chain signals, and the alloimmune response.
    Demirci G; Gao W; Zheng XX; Malek TR; Strom TB; Li XC
    J Immunol; 2002 May; 168(9):4382-90. PubMed ID: 11970980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effect of CD8+CD28- T suppressor cells on the acute rejection responses in rat liver transplantation.
    Liu Y; Chen N; Chen G; You P
    Transplant Proc; 2007 Dec; 39(10):3396-403. PubMed ID: 18089392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-antigen Inoculation in the Testis Promotes Skin Allograft Acceptance Induced by Conventional Costimulatory Blockade via Induction of CD8 + CD122+ and CD4 + CD25+ Regulatory T Cells.
    Cong L; Wang SF; Zhao ZL; Yang RY
    Transplantation; 2016 Apr; 100(4):763-71. PubMed ID: 26569069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
    Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
    J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells.
    Ferrer IR; Wagener ME; Song M; Ford ML
    PLoS One; 2012; 7(7):e40559. PubMed ID: 22792369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil is compatible with CD28/CD154 costimulatory blockade in preventing transplant rejection.
    Vu MD; Li Y; Strom TB; Li XC
    Transplantation; 2005 Mar; 79(6):736. PubMed ID: 15785384
    [No Abstract]   [Full Text] [Related]  

  • 20. Critical, but conditional, role of OX40 in memory T cell-mediated rejection.
    Vu MD; Clarkson MR; Yagita H; Turka LA; Sayegh MH; Li XC
    J Immunol; 2006 Feb; 176(3):1394-401. PubMed ID: 16424166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.